← Back to Screener
CG Oncology, Inc. Common stock (CGON)
Price$70.40
Favorite Metrics
Price vs S&P 500 (26W)61.03%
Price vs S&P 500 (4W)3.34%
Market Capitalization$6.20B
All Metrics
Book Value / Share (Quarterly)$9.33
P/TBV (Annual)4.45x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)176.56%
Cash Flow / Share (Quarterly)$-1.64
Price vs S&P 500 (YTD)72.72%
Net Profit Margin (TTM)-2959.63%
EPS (TTM)$-2.08
10-Day Avg Trading Volume1.33M
EPS Excl Extra (TTM)$-2.08
EPS (Annual)$-2.08
ROI (Annual)-21.31%
Gross Margin (Annual)-15.02%
Net Profit Margin (5Y Avg)-10844.39%
Cash / Share (Quarterly)$9.20
Revenue Growth QoQ (YoY)409.21%
ROA (Last FY)-20.34%
Revenue Growth TTM (YoY)254.70%
EBITD / Share (TTM)$-2.45
ROE (5Y Avg)-23.98%
Operating Margin (TTM)-3515.67%
Cash Flow / Share (Annual)$-1.64
P/B Ratio8.24x
P/B Ratio (Quarterly)4.45x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)1527.37x
Net Interest Coverage (TTM)-35442.00x
ROA (TTM)-21.82%
EPS Incl Extra (Annual)$-2.08
Current Ratio (Annual)24.63x
Quick Ratio (Quarterly)24.09x
3-Month Avg Trading Volume1.23M
52-Week Price Return263.16%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$9.32
P/S Ratio (Annual)1534.67x
Asset Turnover (Annual)0.01x
52-Week High$73.56
Operating Margin (5Y Avg)-12109.07%
EPS Excl Extra (Annual)$-2.08
26-Week Price Return69.78%
Quick Ratio (Annual)24.09x
13-Week Price Return32.28%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)24.63x
Enterprise Value$6,170.587
Asset Turnover (TTM)0.01x
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-3985.02%
Cash / Share (Annual)$9.20
3-Month Return Std Dev48.47%
Net Income / Employee (TTM)$-1
ROE (Last FY)-21.39%
EPS Basic Excl Extra (Annual)$-2.08
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-2.08
ROI (TTM)-22.83%
P/S Ratio (TTM)1534.67x
Pretax Margin (5Y Avg)-10844.39%
Revenue / Share (Annual)$0.05
Tangible BV / Share (Annual)$9.32
Price vs S&P 500 (52W)228.06%
Year-to-Date Return76.85%
5-Day Price Return8.46%
EPS Normalized (Annual)$-2.08
ROA (5Y Avg)-20.45%
Net Profit Margin (Annual)-3985.02%
Month-to-Date Return8.50%
EBITD / Share (Annual)$-2.45
Operating Margin (Annual)-4722.13%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-21.56%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-2.08
P/TBV (Quarterly)4.45x
P/B Ratio (Annual)4.45x
Pretax Margin (TTM)-2959.63%
Book Value / Share (Annual)$9.33
Price vs S&P 500 (13W)29.42%
Beta1.11x
Revenue / Share (TTM)$0.05
ROE (TTM)-22.87%
52-Week Low$19.47
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.19
4.19
4.19
4.19
Industry Peers — Biological Products(88)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
CGONCG Oncology, Inc. Common stock | 1534.67x | 254.70% | — | — | $70.40 |
AMGNAmgen Inc | 5.20x | 9.95% | 73.30% | 2.93% | $350.16 |
GILDGilead Sciences Inc | 5.71x | 2.40% | 78.83% | 133.64% | $135.87 |
ARGXargenx SE American Depositary Shares | 12.59x | 89.56% | 150.91% | — | $834.45 |
BNTXBioNTech SE American Depositary Share | 9.06x | -11.81% | 84.21% | — | $105.19 |
BIIBBiogen Inc. Common Stock | 2.72x | 2.22% | 75.69% | -18.77% | $183.34 |
MRNAModerna, Inc. Common Stock | 10.91x | -39.93% | 70.32% | — | $54.59 |
NBIXNeurocrine Biosciences Inc | 4.64x | 21.45% | 98.18% | 2.31% | $131.59 |
EXELExelixis Inc | 4.89x | 6.85% | 96.39% | 31.10% | $43.61 |
TECHBio-Techne Corp. | 7.72x | 1.64% | 66.60% | -20.58% | $60.58 |
IBRXImmunityBio, Inc. Common Stock | 74.42x | 668.31% | 99.34% | — | $8.20 |
About
CG Oncology is a late-stage biopharmaceutical company developing cretostimogene grenadenorepvec, an intravesical oncolytic immunotherapy for non-muscle-invasive bladder cancer. The candidate is in two Phase 3 trials targeting BCG-unresponsive and intermediate-risk patients, along with a Phase 2 study combining the therapy with checkpoint inhibition. The treatment aims to offer a bladder-sparing alternative to surgery for qualifying patients.